Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients - a Randomized Non-blinded Two-arm Phase III Prospective Clinical Trial (TAB-2 Study).
Tata Memorial Centre
220 participants
Jul 21, 2023
INTERVENTIONAL
Conditions
Summary
This is a randomized, open-label, two-arm, Phase III clinical trial evaluating the efficacy and safety of trastuzumab plus chemotherapy versus chemotherapy alone as first-line treatment in patients with HER2-positive advanced or metastatic biliary tract cancers (BTC). HER2-positive BTCs represent a molecular subset of these rare cancers, associated with poor prognosis and limited treatment options. Eligible patients with histologically confirmed HER2-positive (IHC 3+ or IHC 2+ with FISH amplification) unresectable or metastatic biliary tract adenocarcinoma-including gallbladder cancer, intrahepatic, and perihilar cholangiocarcinoma-will be randomized in a 1:1 ratio. Participants in the intervention arm (Arm A) will receive either gemcitabine and cisplatin with or without nab-paclitaxel plus trastuzumab, while those in the control arm (Arm B) will receive chemotherapy alone (gemcitabine + cisplatin with or without nab-paclitaxel). Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, or death. The primary endpoint is 6-month progression-free survival (PFS). Secondary endpoints include overall survival (OS), response rate (RR), quality of life (QOL), and adverse event (AE) profiles. The study aims to enroll 196 patients across a single center in India over a period of 5 years, with an additional 6-month follow-up. This trial builds on earlier Phase II findings suggesting improved outcomes with trastuzumab in HER2-positive BTC and aims to provide the first randomized evidence for the benefit of HER2-targeted therapy in this setting.
Eligibility
Inclusion Criteria16
- Histologically confirmed adenocarcinoma of the biliary tract, with the following specifications -
- Biliary tract cancers include gallbladder cancer, intrahepatic cholangiocarcinoma, and perihilar cholangiocarcinoma.
- HER2-positive by IHC or FISH
- Age >=18 years.
- ECOG performance status 0 - 2.
- Unresectable or metastatic cancer.
- Patient does not have any contraindications to receive chemotherapy or trastuzumab.
- Adequate hematological, hepatic, and renal function parameters- Hematological- Hb> 80 g/L, ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L. Liver functions- bilirubin ≤ 2 x upper limit normal (ULN), AST/ALT ≤ 5 x ULN, alkaline phosphatase ≤ 6 x upper limit normal (ULN) S. albumin ≥ 30 g/L.
- Renal function- Creatinine ≤ 1.5 ULN, Creatinine clearance >= 30 mL/min.
- Normal cardiac ejection fraction and cardiac function, as assessed by echocardiography, ejection fraction (EF) >=50% or above the lower limit of normal. ECG with no clinically relevant abnormalities.
- Women of childbearing age should have a negative pregnancy test at the time of randomization and should be willing to use adequate contraception during the treatment phase of the trial.
- Subjects must provide written informed consent prior to the performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up assessments and procedures.
- Subjects who have received adjuvant chemotherapy will be considered eligible provided that therapy is completed more than 12 months before study enrollment. Patients who have received radiation therapy and surgery will also be eligible provided the interventions have been completed 3 and 2 weeks, respectively, before enrolment in the study.
- Negative serum pregnancy test (if applicable) and willing for adequate contraception.
- At least one measurable disease according to RECIST criteria.
- Life expectancy of at least 12 weeks.
Exclusion Criteria11
- Distal cholangiocarcinoma
- Known hypersensitivity or contraindications against gemcitabine, cisplatin, Nab- paclitaxel, or trastuzumab.
- Clinically significant active coronary heart disease, cardiomyopathy, or congestive heart failure, NYHA III-IV.
- Clinically significant valvular defect.
- Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix.
- Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.
- Baseline neuropathy > NCI Grade I.
- Subject pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment.
- Received prior chemotherapy within 1 year.
- Any active ILD/ history of lung illness requiring bronchodilator drugs.
- Patients with prior chemotherapy for metastatic disease will be ineligible for enrollment in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Inj Trastuzumab given in a dose of 8mg/kg intravenously over 90 mins as first dose and subsequent doses at a dose of 6mg/kg intravenously over 30-60 minutes in 3 weekly cycle along with standard of care chemotherapy
Gemcitabine + cisplatin OR Gemcitabine-cisplatin-Nab-Paclitaxel given as a standard of care, chemotherapy as per the institutional guidlines
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07062263